ForPatients

by Roche

Pancreatic Ductal Adenocarcinoma

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Trial Status Trial Runs In Trial Identifier

Recruiting 8 Countries NCT05968326 2022-502404-73-00

GO44479

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anticancer treatment for PDAC and have no evidence of disease after surgery.

Genentech, Inc. Sponsor		Phase 2 Phase	
NCT05968326 2022-502404-73-00 GO44479 Trial Identifiers			
Eligibility Criteria:			
Gender All	Age >=18 Years		Healthy Volunteers